Argos Therapeutics (ARGS) Getting Somewhat Positive News Coverage, Report Shows

Press coverage about Argos Therapeutics (NASDAQ:ARGS) has trended somewhat positive recently, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Argos Therapeutics earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 44.9439558374934 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the headlines that may have impacted Accern’s analysis:

Separately, ValuEngine upgraded shares of Argos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating and three have issued a hold rating to the company. Argos Therapeutics presently has an average rating of “Hold” and a consensus price target of $24.00.

Shares of Argos Therapeutics (ARGS) traded down $0.08 on Wednesday, hitting $1.37. 274,500 shares of the stock were exchanged, compared to its average volume of 859,410. The company has a debt-to-equity ratio of -1.46, a current ratio of 2.29 and a quick ratio of 2.29. The stock has a market cap of $5.89, a P/E ratio of -0.06 and a beta of 0.99. Argos Therapeutics has a 1-year low of $1.33 and a 1-year high of $32.00.

TRADEMARK VIOLATION WARNING: This report was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/21/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-argos-therapeutics-args-share-price.html.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Insider Buying and Selling by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply